

William A Weiss

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8249192/publications.pdf>

Version: 2024-02-01

143
papers

21,286
citations

16411

64
h-index

10127

140
g-index

146
all docs

146
docs citations

146
times ranked

32626
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. <i>Nature Medicine</i> , 2022, 28, 333-344.	15.2	105
2	Nuclear tetraspanin 8 promotes breast cancer progression. <i>Cell Research</i> , 2022, 32, 511-512.	5.7	1
3	A SHH secret target of relapsed medulloblastoma: Astrocytes. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	0
4	Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. <i>Cancer Research</i> , 2021, 81, 1627-1632.	0.4	25
5	All eyes on a phosphatase in glioma stem cells. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	0
6	Betacellulin drives therapy resistance in glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 457-469.	0.6	8
7	Conversations on mutism: risk stratification for cerebellar mutism based on medulloblastoma subtype. <i>Neuro-Oncology</i> , 2020, 22, 175-176.	0.6	2
8	Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR Y1068 Phosphorylation. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1328-1339.	1.9	17
9	Utility of Human-Derived Models for Glioblastoma. <i>Cancer Discovery</i> , 2020, 10, 907-909.	7.7	6
10	Translating Basic Science Discoveries into Improved Outcomes for Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 2457-2460.	3.2	8
11	Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1565-1576.	1.9	11
12	Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. <i>Cell Stem Cell</i> , 2019, 25, 433-446.e7.	5.2	56
13	Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints. <i>Blood</i> , 2019, 133, 1119-1129.	0.6	99
14	A CK1 δ Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 1379-1388.	3.2	20
15	Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. <i>Oncogene</i> , 2018, 37, 2850-2862.	2.6	71
16	Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1 "TGF- β " OTX2 "SNAIL via PTEN inhibition. <i>Brain</i> , 2018, 141, 1300-1319.	3.7	22
17	Antisecretory Factor-Mediated Inhibition of Cell Volume Dynamics Produces Antitumor Activity in Glioblastoma. <i>Molecular Cancer Research</i> , 2018, 16, 777-790.	1.5	16
18	Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. <i>Oncogene</i> , 2018, 37, 1561-1575.	2.6	383

#	ARTICLE	IF	CITATIONS
19	Inhibiting 4EBP1 in Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 14-21.	3.2	34
20	Pediatric low-grade gliomas: next biologically driven steps. <i>Neuro-Oncology</i> , 2018, 20, 160-173.	0.6	116
21	EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. <i>Cancer Research</i> , 2018, 78, 6785-6794.	0.4	44
22	Dual HDAC and PI3K Inhibition Abrogates NF κ B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. <i>Cancer Research</i> , 2018, 78, 4007-4021.	0.4	60
23	An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice. <i>Neuro-Oncology</i> , 2018, 20, 1606-1615.	0.6	19
24	Pediatric high-grade glioma: biologically and clinically in need of new thinking. <i>Neuro-Oncology</i> , 2017, 19, now101.	0.6	217
25	A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. <i>Cancer Cell</i> , 2017, 31, 424-435.	7.7	138
26	Cross-activating c-Met/ β 21 integrin complex drives metastasis and invasive resistance in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E8685-E8694.	3.3	60
27	Neuroblastoma Metastases: Leveraging the Avian Neural Crest. <i>Cancer Cell</i> , 2017, 32, 395-397.	7.7	4
28	Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma. <i>Oncogene</i> , 2017, 36, 6306-6314.	2.6	19
29	Glioblastoma cellular cross-talk converges on NF κ B to attenuate EGFR inhibitor sensitivity. <i>Genes and Development</i> , 2017, 31, 1212-1227.	2.7	53
30	Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 131, 495-505.	1.4	29
31	CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. <i>Journal of Clinical Investigation</i> , 2017, 128, 446-462.	3.9	117
32	Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas. <i>Oncotarget</i> , 2017, 8, 583-595.	0.8	24
33	Rational design of a monomeric and photostable far-red fluorescent protein for fluorescence imaging <i>in vivo</i> . <i>Protein Science</i> , 2016, 25, 308-315.	3.1	27
34	BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas. <i>Clinical Cancer Research</i> , 2016, 22, 5312-5321.	3.2	39
35	Cholesterol: An Achilles Heel for Glioblastoma?. <i>Cancer Cell</i> , 2016, 30, 653-654.	7.7	14
36	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	13.7	266

#	ARTICLE	IF	CITATIONS
37	Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. <i>Journal of Neuro-Oncology</i> , 2016, 126, 385-393.	1.4	31
38	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	5.1	274
39	Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. <i>Oncotarget</i> , 2016, 7, 57525-57544.	0.8	42
40	IKK/NF- κ B signaling contributes to glioblastoma stem cell maintenance. <i>Oncotarget</i> , 2016, 7, 69173-69187.	0.8	37
41	Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 111.	1.3	20
42	Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 419-428.	1.9	23
43	A new α -kinase inhibitor design: Prioritizing amphosteric activity above kinase inhibition. <i>Molecular and Cellular Oncology</i> , 2015, 2, e975641.	0.3	5
44	The Genetics of Splicing in Neuroblastoma. <i>Cancer Discovery</i> , 2015, 5, 380-395.	7.7	20
45	Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. <i>Cancer Cell</i> , 2015, 27, 72-84.	7.7	165
46	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. <i>Clinical Cancer Research</i> , 2015, 21, 3750-3758.	3.2	40
47	EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. <i>Nature Neuroscience</i> , 2015, 18, 1236-1246.	7.1	74
48	STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma. <i>Cancer Research</i> , 2015, 75, 4302-4311.	0.4	70
49	Alternative splicing in cancer: implications for biology and therapy. <i>Oncogene</i> , 2015, 34, 1-14.	2.6	247
50	EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. <i>Oncotarget</i> , 2015, 6, 21993-22005.	0.8	27
51	Expression Quantitative Trait Loci and Receptor Pharmacology Implicate Arg1 and the GABA-A Receptor as Therapeutic Targets in Neuroblastoma. <i>Cell Reports</i> , 2014, 9, 1034-1046.	2.9	28
52	Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. <i>International Journal of Cancer</i> , 2014, 134, 2437-2447.	2.3	100
53	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. <i>Nature</i> , 2014, 506, 445-450.	13.7	521
54	The prenatal origins of cancer. <i>Nature Reviews Cancer</i> , 2014, 14, 277-289.	12.8	201

#	ARTICLE	IF	CITATIONS
55	BET Bromodomain Inhibition of <i>MYC</i> -Amplified Medulloblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 912-925.	3.2	296
56	Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma. <i>Science</i> , 2014, 343, 189-193.	6.0	1,147
57	When Deletions Gain Functions: Commandeering Epigenetic Mechanisms. <i>Cancer Cell</i> , 2014, 26, 160-161.	7.7	6
58	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	0.8	263
59	Drugging MYCN through an Allosteric Transition in Aurora Kinase A. <i>Cancer Cell</i> , 2014, 26, 414-427.	7.7	231
60	Glial Progenitors as Targets for Transformation in Glioma. <i>Advances in Cancer Research</i> , 2014, 121, 1-65.	1.9	38
61	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 125, 373-384.	3.9	169
62	Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E1480-9.	3.3	37
63	EGFR Phosphorylates Tumor-Derived EGFRvIII Driving STAT3/5 and Progression in Glioblastoma. <i>Cancer Cell</i> , 2013, 24, 438-449.	7.7	219
64	Starvation favors glioma stem cells. <i>Nature Neuroscience</i> , 2013, 16, 1359-1361.	7.1	4
65	Th-MYCN Mice with Caspase-8 Deficiency Develop Advanced Neuroblastoma with Bone Marrow Metastasis. <i>Cancer Research</i> , 2013, 73, 4086-4097.	0.4	57
66	What underlies the diversity of brain tumors?. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 5-24.	2.7	16
67	Recapitulating human cancer in a mouse. <i>Nature Biotechnology</i> , 2013, 31, 392-395.	9.4	7
68	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	3.9	146
69	Blockade of Glioma Proliferation Through Allosteric Inhibition of JAK2. <i>Science Signaling</i> , 2013, 6, ra55.	1.6	23
70	G34, Another Connection between MYCN and a Pediatric Tumor. <i>Cancer Discovery</i> , 2013, 3, 484-486.	7.7	7
71	It Takes Two to Tango: Dual Inhibition of PI3K and MAPK in Rhabdomyosarcoma. <i>Clinical Cancer Research</i> , 2013, 19, 5811-5813.	3.2	17
72	Neuroblastoma and MYCN. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2013, 3, a014415-a014415.	2.9	480

#	ARTICLE	IF	CITATIONS
73	Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. <i>Cancer Discovery</i> , 2013, 3, 308-323.	7.7	549
74	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2927-2935.	0.8	381
75	Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer. <i>Epigenetics</i> , 2013, 8, 1254-1260.	1.3	16
76	Imaging-based chemical screening reveals activity-dependent neural differentiation of pluripotent stem cells. <i>ELife</i> , 2013, 2, e00508.	2.8	13
77	Kinetics of Inhibitor Cycling Underlie Therapeutic Disparities between EGFR-Driven Lung and Brain Cancers. <i>Cancer Discovery</i> , 2012, 2, 450-457.	7.7	53
78	Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma. <i>Science Translational Medicine</i> , 2012, 4, 115ra3.	5.8	76
79	PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. <i>Neuro-Oncology</i> , 2012, 14, 1146-1152.	0.6	85
80	Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. <i>Genes and Development</i> , 2012, 26, 1780-1796.	2.7	68
81	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	13.7	761
82	Matching mice to malignancy: molecular subgroups and models of medulloblastoma. <i>Child's Nervous System</i> , 2012, 28, 521-532.	0.6	19
83	Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 12722-12727.	3.3	34
84	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
85	High-Throughput Molecular and Histopathologic Profiling of Tumor Tissue in a Novel Transplantable Model of Murine Neuroblastoma: New Tools for Pediatric Drug Discovery. <i>Cancer Investigation</i> , 2012, 30, 343-363.	0.6	9
86	Clonal selection drives genetic divergence of metastatic medulloblastoma. <i>Nature</i> , 2012, 482, 529-533.	13.7	376
87	Cooperative interactions of BRAF ^{V600E} kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 8710-8715.	3.3	77
88	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 515-527.	3.9	66
89	Subgroup-specific alternative splicing in medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 485-499.	3.9	28
90	Distinct Neural Stem Cell Populations Give Rise to Disparate Brain Tumors in Response to N-MYC. <i>Cancer Cell</i> , 2012, 21, 601-613.	7.7	177

#	ARTICLE	IF	CITATIONS
91	Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms. <i>Cancer Letters</i> , 2011, 306, 223-229.	3.2	66
92	Principles and Current Strategies for Targeting Autophagy for Cancer Treatment. <i>Clinical Cancer Research</i> , 2011, 17, 654-666.	3.2	789
93	Genetically engineered murine models “Contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. <i>Seminars in Cancer Biology</i> , 2011, 21, 245-255.	4.3	48
94	Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. <i>Cancer Cell</i> , 2011, 20, 143-157.	7.7	494
95	Asymmetry-Defective Oligodendrocyte Progenitors Are Glioma Precursors. <i>Cancer Cell</i> , 2011, 20, 328-340.	7.7	200
96	PCDH10 is a candidate tumour suppressor gene in medulloblastoma. <i>Child's Nervous System</i> , 2011, 27, 1243-1249.	0.6	21
97	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. <i>Acta Neuropathologica</i> , 2011, 122, 231-240.	3.9	195
98	Vorinostat Increases Expression of Functional Norepinephrine Transporter in Neuroblastoma <i>In Vitro</i> and <i>In Vivo</i> Model Systems. <i>Clinical Cancer Research</i> , 2011, 17, 2339-2349.	3.2	61
99	Targeted Therapy for <i>BRAFV600E</i> Malignant Astrocytoma. <i>Clinical Cancer Research</i> , 2011, 17, 7595-7604.	3.2	143
100	Autophagy and Akt promote survival in glioma. <i>Autophagy</i> , 2011, 7, 536-538.	4.3	47
101	Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. <i>Neuro-Oncology</i> , 2011, 13, 384-392.	0.6	139
102	Radiation dose estimation using preclinical imaging with α -metaiodobenzylguanidine (MIBG) PET. <i>Medical Physics</i> , 2010, 37, 4861-4867.	1.6	60
103	Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma. <i>Science Signaling</i> , 2010, 3, ra81.	1.6	253
104	Non-Stem Cell Origin for Oligodendroglioma. <i>Cancer Cell</i> , 2010, 18, 669-682.	7.7	211
105	Myc proteins as therapeutic targets. <i>Oncogene</i> , 2010, 29, 1249-1259.	2.6	177
106	miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. <i>Nature Medicine</i> , 2010, 16, 1134-1140.	15.2	180
107	Intratumoral Therapy of Glioblastoma Multiforme Using Genetically Engineered Transferrin for Drug Delivery. <i>Cancer Research</i> , 2010, 70, 4520-4527.	0.4	36
108	Pleiotropic role for <i>MYCN</i> in medulloblastoma. <i>Genes and Development</i> , 2010, 24, 1059-1072.	2.7	146

#	ARTICLE	IF	CITATIONS
109	A translational end-run for a rare, genetically enigmatic tumor. <i>Cancer Biology and Therapy</i> , 2009, 8, 2396-2397.	1.5	0
110	Whole-Body <i>Sleeping Beauty</i> Mutagenesis Can Cause Penetrant Leukemia/Lymphoma and Rare High-Grade Glioma without Associated Embryonic Lethality. <i>Cancer Research</i> , 2009, 69, 8429-8437.	0.4	72
111	Adenovirus-mediated <i>hPNPase</i> gene transfer as a therapeutic strategy for neuroblastoma. <i>Journal of Cellular Physiology</i> , 2009, 219, 707-715.	2.0	13
112	Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. <i>Oncogene</i> , 2009, 28, 3121-3131.	2.6	87
113	PI3K Signaling in Glioma—Animal Models and Therapeutic Challenges. <i>Brain Pathology</i> , 2009, 19, 112-120.	2.1	110
114	The Side Story of Stem-like Glioma Cells. <i>Cell Stem Cell</i> , 2009, 4, 191-192.	5.2	8
115	EGFR Signals to mTOR Through PKC and Independently of Akt in Glioma. <i>Science Signaling</i> , 2009, 2, ra4.	1.6	153
116	Involvement of RhoA, ROCK I and myosin II in inverted orientation of epithelial polarity. <i>EMBO Reports</i> , 2008, 9, 923-929.	2.0	106
117	Chemotherapy-Induced Apoptosis in a Transgenic Model of Neuroblastoma Proceeds Through p53 Induction. <i>Neoplasia</i> , 2008, 10, 1268-IN34.	2.3	57
118	Characterization of structurally distinct, isoform-selective phosphoinositide 3-kinase inhibitors in combination with radiation in the treatment of glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 841-850.	1.9	66
119	BMPs oppose Math1 in cerebellar development and in medulloblastoma: Figure 1.. <i>Genes and Development</i> , 2008, 22, 693-699.	2.7	27
120	Malignant Progression and Blockade of Angiogenesis in a Murine Transgenic Model of Neuroblastoma. <i>Cancer Research</i> , 2007, 67, 9435-9442.	0.4	58
121	A Dual Phosphoinositide-3-Kinase/mTOR Inhibitor Cooperates with Blockade of Epidermal Growth Factor Receptor in <i>PTEN</i> -Mutant Glioma. <i>Cancer Research</i> , 2007, 67, 7960-7965.	0.4	199
122	Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. <i>Journal of Cellular Biochemistry</i> , 2007, 102, 1529-1541.	1.2	34
123	Recognizing and exploiting differences between RNAi and small-molecule inhibitors. <i>Nature Chemical Biology</i> , 2007, 3, 739-744.	3.9	260
124	Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. <i>Nature Chemical Biology</i> , 2007, 3, 229-238.	3.9	190
125	A Pharmacological Map of the PI3-K Family Defines a Role for p110 in Insulin Signaling. <i>Cell</i> , 2006, 125, 733-747.	13.5	1,074
126	Chemical genetic approaches to the development of cancer therapeutics. <i>Current Opinion in Genetics and Development</i> , 2006, 16, 85-91.	1.5	3

#	ARTICLE	IF	CITATIONS
127	Brain Tumors in S100 β -v-erbB Transgenic Rats. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 1111-1117.	0.9	13
128	Childhood tumors of the nervous system as disorders of normal development. <i>Current Opinion in Pediatrics</i> , 2006, 18, 634-638.	1.0	92
129	A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. <i>Cancer Cell</i> , 2006, 9, 341-349.	7.7	575
130	Isoform Specific Inhibitors of PI3 Kinase in Glioma. <i>Cell Cycle</i> , 2006, 5, 2301-2305.	1.3	33
131	Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma. <i>Cancer Research</i> , 2006, 66, 8139-8146.	0.4	186
132	Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. <i>Nature Genetics</i> , 2005, 37, 645-651.	9.4	148
133	RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. <i>Oncogene</i> , 2005, 24, 829-837.	2.6	41
134	Shared Epigenetic Mechanisms in Human and Mouse Gliomas Inactivate Expression of the Growth Suppressor SLC5A8. <i>Cancer Research</i> , 2005, 65, 3617-3623.	0.4	63
135	Mechanisms of embryonal tumor initiation: Distinct roles for MycN expression and MYCN amplification. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 12664-12669.	3.3	137
136	Can mouse models for brain tumors inform treatment in pediatric patients?. <i>Seminars in Cancer Biology</i> , 2004, 14, 71-77.	4.3	1
137	Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1394-1403.	3.0	96
138	Neural Stem Cell Biology May Be Well Suited for Improving Brain Tumor Therapies. <i>Cancer Journal (Sudbury, Mass)</i> , 2003, 9, 189-204.	1.0	58
139	Chemical Genetic Blockade of Transformation Reveals Dependence on Aberrant Oncogenic Signaling. <i>Current Biology</i> , 2002, 12, 1386-1394.	1.8	28
140	A head holder for magnetic resonance imaging that allows the stereotaxic alignment of spontaneously occurring intracranial mouse tumors. <i>Journal of Neuroscience Methods</i> , 2002, 116, 1-7.	1.3	11
141	Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. <i>Oncogene</i> , 2002, 21, 7453-7463.	2.6	66
142	Genetics of brain tumors. <i>Current Opinion in Pediatrics</i> , 2000, 12, 543-548.	1.0	20
143	Targeted expression of MYCN causes neuroblastoma in transgenic mice. <i>EMBO Journal</i> , 1997, 16, 2985-2995.	3.5	709